<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01377779</url>
  </required_header>
  <id_info>
    <org_study_id>2*13/09</org_study_id>
    <nct_id>NCT01377779</nct_id>
  </id_info>
  <brief_title>Efficiency of Intercoat (Oxiplex/AP Gel)in Decreasing Intrauterine Adhesions</brief_title>
  <official_title>Intercoat (Oxiplex/AP Gel) for Preventing Intrauterine Adhesions Following Operative Hysteroscopy for Suspected Retained Products of Conception - a Prospective Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective single blind randomized controlled pilot study was designed to
      investigate whether the biological barrier Intercoat (Oxiplex/AP gel) reduces formation of
      intrauterine adhesions following hysteroscopic treatment for retained products of conception.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty women randomly divided equally into those who received Intercoat following
      hysteroscopic treatment for retained products of conception (study group) and those who did
      not receive the gel (controls). Safety and efficacy of the preparation were evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of intrauterine application of Intercoat</measure>
    <time_frame>18 months</time_frame>
    <description>women treated by Intercoat following their hysteroscopic procedure were followed for immediate and late adverse effects; fever, increased intrauterine adhesion formation upon follow up and changes in menstrual pattern</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy of intrauterine application of Intercoat gel in reducing adhesion formation following hysteroscopic treatment for retained products of conception</measure>
    <time_frame>14 months</time_frame>
    <description>intrauterine adhesions were graded according to the AFS score upon hysteroscopic follow up 6-8 weeks following initial treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asherman Syndrome</condition>
  <arm_group>
    <arm_group_label>Intercoat treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women treated by Intercoat gel following hysteroscopy for retained products of conception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No additional treatment following hysteroscopy was performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxiplex/AP gel</intervention_name>
    <description>Intrauterine application of Intercoat following hysteroscopy</description>
    <arm_group_label>Intercoat treatment</arm_group_label>
    <other_name>Intercoat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>No intrauterine application of Intercoat following hysteroscopy</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Distention media</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 50 years

          -  Availability of the results of vaginal ultrasound or diagnostic hysteroscopy

        Exclusion Criteria:

          -  Signs of infection upon admission

          -  Ongoing pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moty Pansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asaf Harofe MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asaf Harofe MC</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>June 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2011</study_first_posted>
  <last_update_submitted>June 20, 2011</last_update_submitted>
  <last_update_submitted_qc>June 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Moty Pansky, MD</name_title>
    <organization>Asaf Harofe MC</organization>
  </responsible_party>
  <keyword>Oxiplex/AP gel</keyword>
  <keyword>Prevention of Asherman's syndrome</keyword>
  <keyword>Intra uterine adhesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Adhesions</mesh_term>
    <mesh_term>Gynatresia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

